Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
BCAB Stock — Bioatla Inc
Bioatla Inc (BCAB)
Updated October 16, 2026.
BCAB is a Stock. Total return is -99.9% over the past 5.8 years, 223.5 points behind SPY at 123.6%.
BioAtla is a clinical-stage biopharmaceutical company developing antibody-based cancer therapeutics, with lead candidates in development for solid tumors including sarcoma, lung cancer, and melanoma. The company does not currently distribute to shareholders. BioAtla appeals to investors with high risk tolerance seeking exposure to early-stage oncology drug development.
BCAB performance versus SPY
Price and return data through 2026-10-16.
Total return is -99.9% over the past 5.8 years, 223.5 points behind SPY at 123.6%. Over the past year its total return — price change plus distributions reinvested — is -96.3%. Its deepest 1-year drawdown was 98.2%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -43.3% | — |
| 3M | -65.9% | — |
| 6M | -72.3% | — |
| YTD | -95.2% | — |
| 1Y | -96.3% | — |
| 2Y CAGR | — | -88.20% |
| 3Y CAGR | — | -74.70% |
| 5Y CAGR | — | -75.10% |
| Since inception (5.8 years) | -99.9% | -70.10% |
BCAB key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 12/16/2020
- Distribution frequency
- None
- Last close
- $1.36 (as of 2026-10-16)
- Market cap
- $2,265,896
- Average volume
- 1412.0
- Beta
- 0.629
- Payout ratio
- 0.0%
- EPS
- $-25.23
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
BCAB risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 98.2%.
Who may consider BCAB — and who may not
It is a weaker fit for investors who need monthly cash flow (BCAB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on BCAB
Frequently asked questions
Does BCAB pay monthly?
No. BCAB does not currently distribute.
When does BCAB pay a dividend?
BCAB does not currently distribute.
How has BCAB performed?
Total return is -99.9% over the past 5.8 years, 223.5 points behind SPY at 123.6%. Over the past year its total return — price change plus distributions reinvested — is -96.3%. Its deepest 1-year drawdown was 98.2%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.